tcsc6325 JD-5037

JD-5037 is a novel, peripherally restricted CB₁R antagonist with an IC₅₀ of 1.5 nM.

IC50 & Target: IC50: 1.5 nM (CB₁R)^[1]

In Vivo: JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice^[2]. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice^[3].